MiRXES Welcomes Genomics Expert to Scientific Advisory Board
Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, has joined the Scientific Advisory Board of MiRXES to help advance its development of RNA-powered multi-omics solutions for research and diagnostics.
SINGAPORE, 28 July 2021 – MiRXES Pte Ltd, a biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests, announced today the appointment of Dr Holger Heyn, an expert in single-cell genomics and spatial transcriptomics, as a Scientific Advisory Board (SAB) member. The addition of Dr Heyn to the MiRXES SAB will strengthen the company’s scientific expertise in the areas of transcriptomics, epigenomics, and genomics, thus accelerating its development of RNA-powered multi-omics solutions for research and diagnostics.
Dr Heyn is the Leader of the Single Cell Genomics Team at the Spanish National Centre for Genomic Analysis (CNAG-CRG) in Barcelona, Spain. His group is at the forefront of genome research, applying single-cell (spatial) transcriptomics, epigenomics and genomics techniques to immuno-oncology research and Human Cell Atlas (HCA) projects. The HCA seeks to describe the cellular basis of the healthy human system as a reference to pinpoint cell types and alterations driving diseases. Dr Heyn co-chairs the Standards and Technology working group of the HCA, leads the atlas of the B-cell lineage and contributes to the atlases of the pancreas and kidney. He has authored 77 publications with a total of more than 10,000 citations (with a H-index of 46) and has previously contributed to the European Epigenome (BLUEPRINT) and The Cancer Genome Atlas (TCGA) projects.
“I am absolutely delighted to join the MiRXES SAB. I look forward to working together with the other SAB members and MiRXES management to push the boundaries of high-resolution diagnostics and fulfil our joint goal to further personalize medicine,” said Dr Heyn, who is also scientific co-founder of Omniscope, a systems diagnostics company that reads the immune system to detect diseases early and monitor patients’ health over time.
“We are honored to welcome Dr Holger Heyn to our SAB. His expertise in the exciting new genomic research frontiers of single-cell genomics and spatial transcriptomics is a significant addition to the knowledge base of our SAB which include internationally-recognized experts in the areas of RNA biology, oncology, liquid biopsy, and molecular pathology,” said Dr Lihan ZHOU, Co-founder and CEO of MiRXES.
More information on the MiRXES SAB here: https://mirxes.com/scientific-advisory-board/
About MiRXES
Founded in 2014 as a spin-off from Singapore’s Agency for Science, Technology, and Research (A*STAR) with strong support from the National University of Singapore (NUS), MiRXES is a leading developer of RNA-powered tests for disease early detection, with strong pipelines in multiple cancer types, as well as in cardiovascular, metabolic and infectious diseases. MiRXES is headquartered in Singapore, with operations in China, Japan and the United States, as well as commercial activities in over 45 countries globally. In 2019, MiRXES launched GASTROClear, the world’s first microRNA blood test for early detection of gastric cancer. The MiRXES’s multi-cancer early detection pipeline includes screening tests for lung, colorectal, liver, and breast cancer. In response to the COVID-19 pandemic in 2020, MiRXES worked closely with A*STAR, Diagnostics Development Hub (DxD) and Tan Tock Seng Hospital (TTSH) to mass produce Fortitude Kit, Singapore’s first authorised COVID-19 RT-PCR test. Since February 2020, more than 7 million Fortitude Kits have been deployed globally.
For more information, visit www.mirxes.com
Follow us on LinkedIn @ https://www.linkedin.com/company/mirxes/